Core Insights - 2026 is anticipated to be a significant year for Genmab, particularly regarding its late-stage pipeline [1] - The focus will be on three brands: EPKINLY, Rina-S, and petosemtamab, all of which have received FDA breakthrough therapy designation [1] Company Pipeline - Each of the three brands is expected to provide meaningful data in 2025, which is crucial for investor attention [1] - The FDA breakthrough therapy designation for all three brands highlights their potential in the market [1]

Summary of Genmab FY Conference Call - March 11, 2026 Company Overview - **Company**: Genmab (NasdaqGS: GMAB) - **Key Focus**: Late-stage pipeline products including EPKINLY, Rina-S, and petosemtamab Key Points Industry and Pipeline Developments - **2026 Significance**: A pivotal year for Genmab with multiple important readouts expected from its late-stage pipeline [2][3] - **FDA Breakthrough Therapy Designation**: All three key products (EPKINLY, Rina-S, petosemtamab) have received this designation, enhancing their development prospects [2] EPKINLY - **Upcoming Readouts**: - Potential full approval for refractory DLBCL in the first half of 2026 - Frontline DLBCL readout expected later in 2026 [4][10] - **Confidence in Trials**: High confidence in upcoming trials despite previous monotherapy trial not meeting overall survival endpoints due to confounding factors [5][6] - **Primary Endpoint**: Progression-Free Survival (PFS) is the primary endpoint for the upcoming trials, which is aligned with regulatory expectations [8] - **Commercial Potential**: If successful, EPKINLY could significantly expand its market, potentially reaching an additional 90,000 to 100,000 patients in frontline settings [13] Rina-S - **Key Study**: RAINFOL-01 study for second-line plus ovarian cancer is set to report in the second half of 2026 [22] - **Efficacy Data**: Previous data showed an overall response rate (ORR) exceeding 50%, with confidence in replicating this in upcoming trials [23] - **Market Opportunity**: Combined patient population for ovarian and endometrial cancer is approximately 120,000, with a favorable split [24] Petosemtamab - **Expected Data**: Anticipated readouts from one or two head and neck cancer trials in the second half of 2026 [30] - **Efficacy Metrics**: Previous data indicated a 63% overall response rate when combined with pembrolizumab, significantly higher than pembrolizumab monotherapy [32] - **Future Plans**: Plans to initiate a phase 3 trial in locally advanced head and neck cancer by the end of 2026 [33] Financial Outlook - **Peak Year Sales Estimates**: - EPKINLY: $3 billion+ - Rina-S: $2 billion+ - Petosemtamab: Multi-billion range [41] - **Growth Prospects**: Strong growth anticipated even after the loss of DARZALEX royalties, supported by a robust pipeline and ongoing clinical development plans [42] Operational Strategy - **Market Approach**: Genmab is building its own distribution network in key markets (U.S., Japan, Germany) while considering partnerships in other regions [38] - **Operational Efficiency**: The company is confident in managing operational expenses while scaling its business [39] Competitive Landscape - **Differentiation**: Rina-S is positioned as a potential best-in-class asset with a comprehensive clinical profile and ongoing trials across multiple indications [27][29] Additional Insights - **Thought Leader Feedback**: Positive feedback from thought leaders regarding EPKINLY's PFS data and its potential in combination therapies [7][18] - **Regulatory Engagement**: Ongoing discussions with regulators to ensure alignment on trial endpoints and data expectations [8] This summary encapsulates the critical insights and projections discussed during the Genmab FY conference call, highlighting the company's strategic focus on its late-stage pipeline and the anticipated impact on its market position and financial growth.

Core Viewpoint - Several financial institutions have initiated coverage on various companies with differing ratings and price targets, reflecting a mix of optimism and caution regarding their future performance. Group 1: Netflix (NFLX) - Barclays reinstated coverage with an Equal Weight rating and a price target of $115, suggesting that the stock's valuation may benefit from potential estimates upside as the company divests from Warner Bros. assets, but concerns about the rationale behind the bidding remain [1]. Group 2: Beachbody Company (BODI) - Craig-Hallum initiated coverage with a Buy rating and a price target of $15, highlighting the company's effective cost management during its turnaround and multiple growth initiatives, including the retail launch of Shakeology, P90X, and Insanity products, as well as a new P90X program after 20 years and a fitness program targeting 180 million inactive Americans [1]. Group 3: Forgent Power Solutions (FPS) - Goldman Sachs initiated coverage with a Buy rating and a price target of $48, noting that Forgent is among the few companies capable of providing a complete powertrain to data centers, positioning it to benefit as a marginal supplier of capacity. Other firms like KeyBanc, JPMorgan, and TD Cowen also started coverage with Buy-equivalent ratings, while Morgan Stanley and Baird opted for Neutral-equivalent ratings [1]. Group 4: Bob's Discount Furniture (BOBS) - KeyBanc initiated coverage with an Overweight rating and a price target of $28, indicating a 32% upside potential. The firm views Bob's as a compelling small-cap growth story, with several other institutions also starting coverage with Buy-equivalent ratings, while Goldman Sachs and Baird provided Neutral-equivalent ratings [1]. Group 5: Genmab (GMAB) - Wells Fargo initiated coverage with an Overweight rating and a price target of $40, expressing confidence that the upcoming readouts for Epkinly and petosemtamab are largely de-risked based on Phase 2 data [1].

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [25][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [26][30] - Sales of proprietary medicines totaled $632 million, up 54% year-over-year, accounting for approximately 28% of total revenue growth [16][25] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for 2025, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - Tivdak generated $164 million in sales, a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in over 65 countries, nearly all featuring the dual indication [17] - The U.S. market saw increased uptake for Epkinly, particularly in community settings, with a majority of health systems ordering from multiple sites [18] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation [31] - The company anticipates continued momentum in Epkinly and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [27][30] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, which have multi-billion dollar potential [9] - The company is committed to deleveraging, targeting gross leverage below 3x by the end of 2027 [30] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results? - Management confirmed that the study showed positive progression-free survival but missed overall survival, and discussions with regulatory agencies are ongoing regarding the next steps [34][36] Question: Update on outpatient data for Epkinly? - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [43][46] Question: Expectations for Rina-S pivotal phase two readout? - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [51][54] Question: Expectations for EPCORE DLBCL 4 trial? - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [58][60] Question: Thoughts on pembro approval in PROC and implications for Rina-S? - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [62][64] Question: Confirmation on interim results for Epkinly frontline DLBCL trial? - Management reiterated that the readout for the study is expected to happen in 2026 [55][68]

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][29] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [16][24] Business Line Data and Key Metrics Changes - EPKINLY achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - TIVDAK generated $164 million in sales, representing a 26% year-over-year increase, highlighting its continued market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - EPKINLY closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [17] - TIVDAK's launch in Germany showed strong, consistent uptake and positive physician feedback, indicating a successful entry into new markets [21][22] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation and investment prioritization [30][29] - The company anticipates continued momentum in EPKINLY and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [26][29] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating significant long-term growth potential [9] - Management highlighted the importance of maximizing first-mover advantage in second-line follicular lymphoma in the U.S. and anticipated approvals in Europe and Japan [19][20] Q&A Session Summary Question: Next steps for EPKINLY following EPCORE DLBCL-1 study results - Management confirmed that the 05 study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies regarding the data set [33][34] Question: Update on outpatient data for EPKINLY - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [41][44] Question: Expectations for Rina-S pivotal phase II readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [50][51] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [55][56] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [61] Question: EPKINLY frontline DLBCL trial expectations - Management emphasized that the primary endpoint is progression-free survival, with expectations for EPKINLY to be transformative in combination with R-CHOP [66][68]

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][25] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][27] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [14][24] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [15][24] - Tivdak generated $164 million in sales, representing a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [19][20] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [15] - The U.S. market saw increased uptake for Epkinly, particularly following its approval in second-line follicular lymphoma [17][18] - Tivdak's launch in Germany showed strong uptake, with positive physician feedback [20] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines [5][24] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, contributing to sustainable growth [6][25] - The focus for 2026 includes advancing proprietary portfolio impact, expanding market footprint, and preparing for multiple product launches [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027 [29] - The company anticipates continued revenue growth driven by Epkinly and its royalty portfolio, with a guidance of 14% total revenue growth for 2026 [26][28] - Management highlighted the importance of maintaining substantial profitability while investing in growth opportunities [27][28] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating multi-billion dollar potential [7] - The anticipated data readouts in 2026 are expected to set the stage for multiple important product launches and line extensions in 2027 [8][10] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results - Management confirmed that the study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies about the data [31][33] Question: Update on outpatient data for Epkinly - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [40][42] Question: Expectations for Rina-S pivotal phase two readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [47][49] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [53][55] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [57][59] Question: Clarification on phase 3 for petosemtamab - Management confirmed that the phase 3 studies have dual endpoints of overall response rate and overall survival, which are standard in areas of unmet medical need [75]

Core Viewpoint - Genmab A/S has decided to discontinue the clinical development of acasunlimab to focus on more promising late-stage opportunities in its portfolio [1][2]. Group 1: Clinical Development Decision - The decision to halt acasunlimab's development follows a thorough assessment of the competitive landscape and aims to concentrate resources on programs with the highest potential impact [1][2]. - Acasunlimab was involved in four cancer trials, including a Phase 3 study in non-small cell lung cancer and two Phase 2 trials in melanoma and non-small cell lung cancer [4]. Group 2: Financial Implications - The discontinuation of acasunlimab does not affect Genmab's full-year 2025 financial guidance [3]. - Analyst estimates previously modeled peak sales of approximately $300 million for acasunlimab, which was considered a minimal contribution to the company's overall revenue potential [5]. Group 3: Focus on Other Programs - Genmab will redirect its focus to other late-stage programs, including Epkinly (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S), which are advancing in development [2]. - The combined peak sales potential for these three lead assets is estimated at $8 billion, indicating significant upside for Genmab [5]. Group 4: Market Reaction - Following the announcement, Genmab shares experienced a decline of 2.05%, trading at $32.73 [6].

Core Viewpoint - Genmab A/S has decided to discontinue the clinical development of acasunlimab to focus on higher-value opportunities in its late-stage pipeline, despite encouraging clinical data observed to date [1][2][7]. Group 1: Decision and Strategic Focus - The decision to halt the acasunlimab program is part of Genmab's strategic focus on maximizing value in its late-stage portfolio [1][7]. - Genmab will redirect resources towards programs with higher potential impact, specifically EPKINLY (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S), which are currently in late-stage development [1][2]. Group 2: Financial Guidance - This decision will not affect Genmab's full-year 2025 financial guidance, indicating stability in the company's financial outlook despite the program discontinuation [3][7]. Group 3: Company Background - Genmab is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases, with over 25 years of experience in advancing various antibody-based therapeutic formats [4][5]. - The company has a strong late-stage clinical pipeline and aims to deliver transformative medicines to patients [4].

Core Insights - Genmab A/S has successfully completed the tender offer to acquire all outstanding common shares of Merus N.V. for $97 per share, marking a significant step in its strategy to transition to a wholly owned model and enhance revenue diversification [1][4] - The acquisition is expected to bolster Genmab's position as a global biotechnology leader, particularly through the integration of Merus' lead asset, petosemtamab, which is anticipated to have a substantial impact on head and neck cancer treatment [2][3] - Genmab projects that petosemtamab will contribute to EBITDA with an annual sales potential of at least $1 billion by 2029, with expectations for multi-billion-dollar revenue potential thereafter [3][8] Transaction Details - As of the expiration time on December 11, 2025, 71,463,077 shares of Merus, representing 94.2% of its outstanding shares, were validly tendered [4] - A subsequent offering period of ten business days has been initiated, allowing additional shares to be purchased at the same price of $97 per share [5] - Following the completion of the subsequent offering period, Genmab plans to finalize the acquisition of 100% of Merus through additional transactions [6] Strategic Fit - The addition of petosemtamab aligns with Genmab's expertise in antibody therapy development and commercialization in oncology, enhancing its late-stage pipeline [3][8] - Genmab aims to launch petosemtamab in 2027, contingent on clinical results and regulatory approvals, with plans for further development in other therapeutic areas [3]

Core Insights - Merus N.V. and Halozyme Therapeutics, Inc. have entered into a global non-exclusive collaboration and license agreement to develop and potentially commercialize the subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody [1][2][3] Company Overview - Halozyme is a biopharmaceutical company known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, aiming to improve patient experience and treatment efficiency [4][5] - Merus specializes in developing innovative full-length multispecific antibodies and antibody drug conjugates, referred to as Multiclonics, which have shown promising results in clinical studies [7][8] Collaboration Details - Under the agreement, Merus will make an upfront payment to Halozyme, along with potential future milestone payments based on commercial and sales achievements, if approved [3] - Halozyme is entitled to receive low to mid-single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term [3] Clinical Potential - Petosemtamab has shown encouraging results in clinical studies across various solid tumor cancers and is positioned to potentially become a first and best-in-class treatment for head and neck cancer and other indications [2][3]